Introduction {#sec1_1}
============

Macular edema (ME) is one of the main vision-threatening complications associated with central retinal vein occlusion (CRVO) \[[@B1]\]. In CRVO, increased intravascular pressure and reduced blood flow in the macular capillaries can lead to dysfunction of the endothelial blood-retinal barrier and to increased vascular permeability, both of which result in ME \[[@B2]\].

Recently published clinical trials have shown that intravitreal dexamethasone (Ozurdex®; Allergan, Irvine, Calif., USA) and ranibizumab (Lucentis®; Novartis Pharma) are effective in the treatment of ME secondary to CRVO \[[@B3], [@B4]\]. Neither of these studies included eyes previously treated with vitrectomy. In vitrectomized eyes, ocular pharmacokinetics and pharmacodynamics are modified with an increase in the clearance of medications from the vitreous. It has been shown that the half-life of drugs after intravitreal injection is reduced in vitrectomized eyes \[[@B5]\]. This result was found after injection of anti-vascular endothelial growth factor (VEGF), used for the treatment of diabetic ME \[[@B6]\].

To address this drawback, a biodegradable dexamethasone drug delivery system was developed (Ozurdex). Ozurdex was designed to provide sustained delivery of 700 mg of preservative-free dexamethasone to the vitreous cavity and retina for up to 180 days \[[@B3]\]. In vitrectomized and nonvitrectomized rabbit eyes, it has been shown that 1 month after implantation of the Ozurdex device, the concentration of dexamethasone in the vitreous cavity is similar \[[@B5]\].

We report a case of complete resolution of cystoid ME secondary to CRVO, refractory to previous treatments with intravitreal bevacizumab, with significant improvement of best-corrected visual acuity (BCVA), in a vitrectomized eye treated with an intravitreal implant of dexamethasone.

Case Report {#sec1_2}
===========

A 62-year-old Caucasian woman presented at the University Eye Clinic at the Policlinico of Catania with a history of vitreoretinal surgery for vitreous hemorrhage in her right eye, secondary to CRVO. Because of the persistence of ME, three months after vitrectomy she received 2 intravitreal injections of bevacizumab 0.5 mg (Avastin®; Genentech/Roche), without functional or anatomical improvement after the injections.

When the patient was first examined at our clinic, 6 months after vitrectomy, she was diagnosed with cystoid ME secondary to CRVO (**fig. [1a](#F1){ref-type="fig"}**). BCVA in the right eye was 1.2 logMAR and central foveal thickness was 672 μm as measured by SD-OCT (spectral domain optical coherence tomography; Spectralis, Heidelberg Engineering, Heidelberg, Germany) (**fig. [2a](#F2){ref-type="fig"}**). Therefore, she received an intravitreal implant of dexamethasone 0.7 mg (Ozurdex).

An improvement in her BCVA to 0.9 logMAR was detected seven days after the injection; central macular thickness, measured by OCT and using the follow-up function, was 389 μm, with a reduction of 283 μm compared to the baseline value (fig. [2b](#F2){ref-type="fig"}).

Six months after the injection of Ozurdex, complete resolution of the ME and retinal hemorrhages was observed (fig. [1b](#F1){ref-type="fig"}); central macular thickness was 203 μm and BCVA improved further to 0.6 logMAR (fig. [2c](#F2){ref-type="fig"}).

Discussion {#sec1_3}
==========

To our knowledge, there are no cases of intravitreal treatment of ME secondary to CRVO in vitrectomized eyes described so far in the literature. Recent studies have evaluated the efficacy of the treatment of diabetic ME with intravitreal therapy in vitrectomized eyes: anti-VEGF failed to show a significant effect \[[@B6]\], while a prospective trial showed the efficacy of intravitreal Ozurdex implantation \[[@B7]\]. The results obtained in this latter study, as well as in our case, may have been caused by the favorable pharmacokinetics of a sustained-release dexamethasone implant.

Interestingly, in this case, the treatment with dexamethasone was effective in one eye with chronic ME refractory to repeated anti-VEGF injections; one of the main mechanisms of chronic ME is the alteration of the functionality of Müller cells. It has been experimentally shown that steroids, by reducing the osmotic swelling of Müller cells, improve the functionality of these cells and reduce ME \[[@B8]\]. Therefore, the dexamethasone implant (Ozurdex) may lead to anatomical and functional improvement also in patients with ME due to retinal vein occlusion, even in long-standing cases \[[@B9]\].

Another finding in our patient was the long-term effect, namely the absence of edema for up to 6 months. After vitrectomy, when the vitreous gel is replaced with a less viscous saline solution, the transport of all molecules and oxygen is facilitated, leading to better oxygenation of the ischemic retinal areas \[[@B10]\].

In conclusion, the dexamethasone implant (Ozurdex) might be an effective treatment option in ME secondary to CRVO, also in vitrectomized eyes.
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![**a** Fundus photography at baseline, before Ozurdex® injection, shows cystoid ME, widespread hemorrhaging and a swollen optic nerve in a vitrectomized eye. **b** Fundus photography 6 months after treatment shows a resolution of intraretinal hemorrhages and no ME.](cop-0003-0030-g01){#F1}

![**a** Baseline Spectralis OCT, before Ozurdex® injection, shows cystoid ME, refractory to 2 injections of Avastin®, in a vitrectomized eye; central retinal thickness was 672 μm. **b** Seven days after the injection of Ozurdex, using the follow-up function, OCT shows a 389-μm reduction in central retinal thickness. **c** Follow-up examination 180 days after Ozurdex injection. OCT shows the resolution of ME with a 469-μm reduction in central retinal thickness, compared to the baseline value.](cop-0003-0030-g02){#F2}
